Malaria case management Plasmodium vivax malaria: a field guide

P. vivax contributes substantially to the malaria burden outside of sub-Saharan Africa.  P.vivax requires medicines  to eliminate both blood-stage and latent liver-stage infection, thereby curing acute malaria as well as preventing relapse. Recently,  single-dose and high does short-course 8-aminoquinoline regimens to prevent relapse have been recommended alongside near-patient diagnostic tests for G6PD activity needed to facilitate safe and effective treatment. 

This field guide aligns with the updated recommendations and incorporates evidence and lessons learned from feasibility studies and pilot implementations to support countries in the timely implementation of the updated WHO P.vivax case management guidelines.